Tech Company Financing Transactions

Portola Pharmaceuticals Funding Round

On 11/22/2011, Portola Pharmaceuticals raised $89 million in investment from Temasek Holdings and private investors.

Transaction Overview

Announced On
11/22/2011
Transaction Type
Venture Equity
Amount
$89,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds will be used primarily to advance betrixaban, a once-daily, oral Factor Xa inhibitor, through Phase 3 clinical development and to advance development of its companion product, PRT064445, a recombinant Factor Xa inhibitor antidote designed to reverse anticoagulant activity in patients treated with Factor Xa inhibitors suffering major bleeds or requiring surgery. Portola plans to initiate a Phase 3 betrixaban program to prevent venous thromboembolism (VTE) in acute medically ill patients in the first half of 2012.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
270 E. Grand Ave.
South San Francisco, CA 94080
USA
Email Address
Overview
Portola Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola has two drug candidates in clinical development.
Profile
Portola Pharmaceuticals LinkedIn Company Profile
Social Media
Portola Pharmaceuticals Company Twitter Account
Company News
Portola Pharmaceuticals News
Facebook
Portola Pharmaceuticals on Facebook
YouTube
Portola Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Financial Officer
Mard Dier
  Mard Dier LinkedIn Profile  Mard Dier Twitter Account  Mard Dier News  Mard Dier on Facebook
Chief Medical Officer
John Lawrence?
  John Lawrence? LinkedIn Profile  John Lawrence? Twitter Account  John Lawrence? News  John Lawrence? on Facebook
VP - Bus. Development
Tao Fu
  Tao Fu LinkedIn Profile  Tao Fu Twitter Account  Tao Fu News  Tao Fu on Facebook
VP - Engineering
Glenn Brame
  Glenn Brame LinkedIn Profile  Glenn Brame Twitter Account  Glenn Brame News  Glenn Brame on Facebook
VP - General Counsel
John Moriarty
  John Moriarty LinkedIn Profile  John Moriarty Twitter Account  John Moriarty News  John Moriarty on Facebook
VP - R & D
John Curnutte
  John Curnutte LinkedIn Profile  John Curnutte Twitter Account  John Curnutte News  John Curnutte on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/22/2011: SoluLink venture capital transaction
Next: 11/22/2011: Marginize venture capital transaction

 

Share this article

 


About Database of VC Transactions

We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary